%0 Journal Article
%A Palmedo, Holger
%A Ahmadzadehfar, Hojjat
%A Eschmann, Susanne
%A Niesen, Andreas
%A Schönberger, Johann
%A Barsegian, Vahé
%A Liepe, Knut
%A Mottaghy, Felix M
%A Guan, Rongjin
%A Pinkert, Joerg
%A Sandström, Per
%A Herrmann, Ken
%T Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study.
%J Journal of nuclear medicine
%V 64
%N 9
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-01321
%P 1392-1398
%D 2023
%Z 2023 Sep;64(9):1392-1398
%X 223Ra, a targeted α-therapy, is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have bone metastases. In the phase 3 ALSYMPCA study, 223Ra prolonged survival and improved quality of life versus placebo. Our real-world study, PARABO, investigated pain and bone pain-related quality of life in patients with mCRPC and symptomatic bone metastases receiving 223Ra in clinical practice. Methods: PARABO was a prospective, observational, noninterventional single-arm study conducted in nuclear medicine centers across Germany (NCT02398526). The primary endpoint was a clinically meaningful pain response (≥2-point improvement from baseline for the worst-pain item score in the Brief Pain Inventory-Short Form). Results: The analysis included 354 patients, who received a median of 6 223Ra injections (range, 1-6). Sixty-seven percent (236/354) received 5-6 injections, and 33
%K 223Ra (Other)
%K bone metastases (Other)
%K castration-resistant prostate cancer (Other)
%K pain response (Other)
%K targeted α-therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37385670
%R 10.2967/jnumed.123.265557
%U https://inrepo02.dkfz.de/record/277292